motolimod
Small moleculeexperimental
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019. — Wikipedia
Clinical trial activity
10 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2008 (NCT00688415)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Brenner Tumor · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Ovarian Epithelial · Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Verrucous · Phase 1
- Colorectal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Graft vs Host Disease · Phase 1
- Hamartoma · Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1/Phase 2
- Melanoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Salivary Gland Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Tongue Neoplasms · Phase 1
Mechanism of action
- Toll-like receptor 8AGONIST
Toll-like receptor 8 agonist
Chemistry & pharmacology
Loading structure…
SMILES
CCCN(CCC)C(=O)C1=Cc2ccc(-c3ccc(C(=O)N4CCCC4)cc3)cc2N=C(N)C1- Mol. weight
- 458.61 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaArray BioPharma ↗
- ChEMBLCHEMBL3301618 ↗
Also known as
- motolimod
- motolimod
- motolimod
- motolimod
- vtx-2337
- vtx-2337
- vtx-2337
- vtx-378
- vtx-378
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04272333 | Early Phase 1 (Phase 1) | May 1, 2020 | Celgene, Presage Biosciences |
| NCT03906526 | Phase 1 | Apr 15, 2019 | Celgene |
| NCT02650635 | Phase 1 | Feb 1, 2016 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT02124850 | Phase 1 | Sep 1, 2014 | University of Pittsburgh, VentiRx Pharmaceuticals Inc. |
| NCT01836029 | Phase 2 | Jul 1, 2013 | University of Chicago, University of Pittsburgh, VentiRx Pharmaceuticals Inc. |
| NCT01666444 | Phase 2 | Oct 1, 2012 | Gynecologic Oncology Group, University of Arizona, VentiRx Pharmaceuticals Inc. |
| NCT01289210 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2011 | Stanford University, VentiRx Pharmaceuticals Inc. |
| NCT01334177 | Phase 1 | Jun 1, 2011 | National Cancer Institute (NCI), University of Washington |
| NCT01294293 | Phase 1 | Mar 1, 2011 | Gynecologic Oncology Group, National Cancer Institute (NCI), NRG Oncology |
| NCT00688415 | Phase 1 | Nov 1, 2008 | VentiRx Pharmaceuticals Inc. |
Showing 10 of 10 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| VentiRx Pharmaceuticals Inc. | For profit | 5 | 5 | 2 | 2008 |
| National Cancer Institute (NCI) | Government | 3 | 0 | 1 | 2011 |
| Celgene | For profit | 2 | 1 | 1 | 2019 |
| Gynecologic Oncology Group | Academic/Hospital | 2 | 1 | 2 | 2011 |
| University of Pittsburgh | Academic/Hospital | 2 | 0 | 2 | 2013 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2016 |
| NRG Oncology | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Presage Biosciences | For profit | 1 | 1 | 1 | 2020 |
| Stanford University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| University of Arizona | Academic/Hospital | 1 | 0 | 1 | 2012 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of Washington | Academic/Hospital | 1 | 1 | 1 | 2011 |
12 organizations
Page 1 / 1